Pathophysiology and thrombokinetics in autoimmune thrombocytopenia.
Studies that have measured platelet survival by autologous platelet labeling with (111)In and (51)Cr have differed in their results. Although all studies have revealed a significant decrease in platelet life span, the rates of platelets entering the circulation, a calculated and inferred determination, have been found to be moderately decreased to as much as five times normal. Several mechanisms have been proposed to explain an apparent decrease in platelet production, including a true decrease due to damage to the megakaryocytes by autoantibody, versus a decrease only in 'effective' production due to intramedullary destruction by the reticuloendothelial system. Recently, the identification of the cytokine, thrombopoietin, has allowed the evaluation of another aspect of the pathophysiology of thrombocytopenic states. Megakaryocyte growth factor levels are increased 10 to 20 times in patients who are thrombocytopenic due to chemotherapy or aplastic anemia, but may be decreased, normal, or only modestly raised in patients with immune platelet destruction. Autologous platelet survival measurements, prior to and while on therapy with a stable platelet count, reveal that removal of part of the reticuloendothelial system with splenectomy leads to increased platelet survival and platelet number. Similar studies reveal that corticosteroid treatment for immune thrombocytopenic purpura (ITP) effectively increases the rate of platelet production but does not change platelet survival. It may be that other therapies are effective by a combination of these mechanisms. Stimulation of thrombopoietin production or administering exogenous cytokine may have a role to play in future management of patients with ITP.
Gernsheimer
T
T
Puget Sound Blood Center and University of Washington School of Medicine, Seattle, Washington 98104, USA. bldbuddy@u.washington.edu
D001792:Blood Platelets / Q000473:pathology; D002470:Cell Survival / Q000187:drug effects; D016207:Cytokines / Q000097:blood / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000097:blood* / Q000209:etiology / Q000628:therapy
D016207:Cytokines